Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 14.3% in March

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 512,684 shares, a decline of 14.3% from the March 15th total of 598,274 shares. Based on an average daily volume of 114,314 shares, the short-interest ratio is currently 4.5 days. Currently, 3.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter valued at $222,000. XTX Topco Ltd raised its holdings in Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after acquiring an additional 36,269 shares during the period. Osaic Holdings Inc. lifted its position in shares of Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after acquiring an additional 13,340 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Marker Therapeutics in the fourth quarter worth about $60,000. Finally, Renaissance Technologies LLC grew its position in shares of Marker Therapeutics by 16.4% during the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on MRKR. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a research report on Friday, March 27th. Finally, Zacks Research cut Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Marker Therapeutics has an average rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Stock Up 5.6%

NASDAQ:MRKR traded up $0.09 during mid-day trading on Friday, hitting $1.70. 79,651 shares of the company traded hands, compared to its average volume of 279,514. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.37. The firm has a market cap of $28.34 million, a price-to-earnings ratio of -2.00 and a beta of 1.47. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.17. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%. Equities analysts predict that Marker Therapeutics will post -0.65 EPS for the current year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.